# Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement

> **NCT00648323** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 80 (actual)

## Conditions studied

- Prostate

## Interventions

- **DRUG:** Doxazosin mysylate GITS

## Key facts

- **NCT ID:** NCT00648323
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2005-01
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00648323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00648323, "Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00648323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*